Description

⚠️ LABORATORY RESEARCH USE ONLY

NOT FOR HUMAN OR ANIMAL CONSUMPTION

This product is intended exclusively for in vitro research and analytical applications in professional laboratory settings.

NOT approved by FDA for human use. NOT for clinical, diagnostic, or therapeutic purposes.

T-GLP2 – Research Peptide for Metabolic and Intestinal Studies

T-GLP2 (30 mg) is a synthetic investigational peptide that combines dual GIP/GLP-1 receptor agonist properties with GLP-2 receptor signaling. This multi-receptor agonist is studied in laboratory research focusing on metabolic pathways, intestinal physiology, and endocrine mechanisms.

Product Specifications – T-GLP2 (30 mg)

Parameter	Specification
Category	Synthetic multi-incretin receptor agonist (GIPR, GLP-1R, GLP-2R) for research
Molecular Formula	Approx. C₂₁₁H₃₂₀N₅₀O₆₁
Molecular Weight	~4813 Da
Peptide Length	~39 amino acids (dual-component structure)
Form & Purity	Lyophilized powder; ≥95% purity (HPLC-verified)
Storage	Lyophilized: −20°C, protected from light/moisture Reconstituted: −80°C
Solubility	Soluble in sterile water or 0.1% acetic acid

Receptor Interaction Profile

T-GLP2 is studied for its interactions with three distinct receptor pathways in laboratory research models:

GIP Receptor (GIPR) – Investigated for glucose-dependent insulin secretion mechanisms and β-cell function studies
GLP-1 Receptor (GLP-1R) – Examined in research on glucagon secretion pathways, gastric motility, and satiety signaling mechanisms
GLP-2 Receptor (GLP-2R) – Studied for intestinal epithelial proliferation, villus morphology, and nutrient absorption pathways

These receptor interactions are investigated in controlled laboratory environments to understand:

Glucose homeostasis mechanisms through combined incretin receptor signaling
Energy balance regulation and appetite signaling pathways
Intestinal barrier function and epithelial integrity in cell culture models
Lipid metabolism and hepatic pathway interactions

Laboratory Research Applications

Metabolic Pathway Research:

Type 2 diabetes research models – β-cell function, insulin sensitivity pathways, glucagon regulation studies
Obesity research – appetite signaling mechanisms, energy balance, adipose tissue metabolism studies
Incretin hormone pathway investigations

Gastrointestinal Research:

GLP-2 receptor activity in intestinal cell proliferation studies
Short bowel syndrome research models and nutrient absorption pathway analysis
Intestinal barrier integrity studies, gut inflammation models, epithelial repair mechanisms
Mucosal growth factor research

Hepatic & Lipid Metabolism Studies:

MASLD/NASH research models – hepatic lipid oxidation pathways, fat trafficking mechanisms
Cardiovascular research – lipid remodeling pathways and atherogenic marker studies
Hepatocyte metabolism and triglyceride pathway research

Neuroendocrine Research:

Hypothalamic satiety signaling pathways and anorexigenic mechanism studies
Central nervous system energy balance regulation research
Neuroinflammation models and cognitive function pathway investigations

Laboratory Handling & Storage Guidelines

Reconstitution Protocol:

Reconstitute under sterile conditions using appropriate aseptic technique
Use sterile water or 0.1% acetic acid as solvent
Create aliquots to prevent repeated freeze-thaw cycles
Store reconstituted solution at −80°C for extended stability

Safety Considerations for Laboratory Use:

Literature on similar incretin-based peptides reports observations in research settings including GI-related effects in animal models (nausea models, gastric emptying studies, GI motility research). Some studies note mild adverse observations including tachycardia models and pancreatitis pathway investigations in GLP-1 receptor research.

Note: These represent research findings from controlled laboratory studies and do not constitute human safety data.

Research References

⚠️ IMPORTANT NOTICE: The following citations represent published scientific research conducted in controlled laboratory and preclinical settings. These studies do not represent approved clinical applications and are provided for research reference only.

Urva, S., Coskun, T., Loh, M. T., et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, randomized, placebo-controlled trial. The Lancet, 400(10366), 1869–1881. https://doi.org/10.1016/S0140-6736(22)02033-5
Drucker, D. J., & Yusta, B. (2014). Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annual Review of Physiology, 76, 561–583. https://doi.org/10.1146/annurev-physiol-021113-170317
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., et al. (2023). Tirzepatide once weekly for obesity – A Phase 3 SURMOUNT-1 trial update. The New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2206038
Drucker, D. J. (2022). Advances in incretin-based therapies for metabolic disease. Nature Reviews Endocrinology, 18(10), 611–622. https://doi.org/10.1038/s41574-022-00763-7

Research Compliance Notice

T-GLP2 (30 mg) is a research peptide for laboratory investigation of multi-incretin receptor pathways, metabolic mechanisms, intestinal physiology, and endocrine signaling systems.

FOR LABORATORY AND INVESTIGATIONAL RESEARCH ONLY. Not approved for human or veterinary therapeutic use. Not for clinical applications. Not for human or animal consumption.

Explore our complete catalog of high-purity, third-party tested research compounds by visiting our main shop page for all your laboratory needs.